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PSD-95, a principal scaffolding component of the
postsynaptic density, is targeted to synapses by
palmitoylation, where it couples NMDA receptor
stimulation to production of nitric oxide (NO) by
neuronal nitric oxide synthase (nNOS). Here, we
show that PSD-95 is physiologically S-nitrosylated.
We identify cysteines 3 and 5, which are palmitoy-
lated, as sites of nitrosylation, suggesting a competi-
tion between these two modifications. In support
of this hypothesis, physiologically produced NO
inhibits PSD-95 palmitoylation in granule cells of
the cerebellum, decreasing the number of PSD-95
clusters at synaptic sites. Further, decreased palmi-
toylation, as seen in heterologous cells treated with
2-bromopalmitate or in ZDHHC8 knockout mice defi-
cient in a PSD-95 palmitoyltransferase, results in
increased PSD-95 nitrosylation. These data support
a model in which NMDA-mediated production of
NO regulates targeting of PSD-95 to synapses via
mutually competitive cysteine modifications. Thus,
differential modification of cysteines may represent
a general paradigm in signal transduction.
INTRODUCTION
PSD-95, the principal protein of postsynaptic densities (PSD), is
a major scaffolding protein that impacts synaptic plasticity (Cho
et al., 1992; Migaud et al., 1998). In addition to maintaining the
molecular architecture of the PSD (Chen et al., 2008), PSD-95
enhances long-term depression (Stein et al., 2003) and is
required for spatial learning in mouse models (Migaud et al.,
1998). N-terminal palmitoylation targets PSD-95 to synapses,
where it clusters AMPA-type glutamate receptors (Chen et al.,
2000) and physically links NMDA receptors to neuronal nitric
oxide synthase (nNOS) (Brenman et al., 1996; Christophersonet al., 1999). This interaction enables calcium that permeates
NMDA receptors to activate nNOS by binding calmodulin asso-
ciatedwith the enzyme (Bredt and Snyder, 1990). Suppression of
PSD-95 expression (Sattler et al., 1999) or inhibition of binding
between PSD-95 and the NMDA receptor with exogenous
peptides (Aarts et al., 2002) reduces NO-mediated excitotoxic-
ity, emphasizing the role of PSD-95 in transducing signals from
the NMDA receptor to nNOS.
PSD-95 also regulates AMPA receptors through its interaction
with stargazin (Chen et al., 2000). This binding is required for
recruitment of AMPA receptors to the synapse (Schnell et al.,
2002). Consistent with this observation, mice deficient in PSD-
95 have decreased AMPA receptor-mediated neurotransmis-
sion (Be´ı¨que et al., 2006). Furthermore, appropriate interactions
between PSD-95 and A kinase-anchoring protein (AKAP) are
required for NMDA-mediated AMPA receptor endocytosis
(Bhattacharyya et al., 2009).
PSD-95 function is regulated by dynamic cycling of palmitoyla-
tion and depalmitoylation (El-Husseini et al., 2002). Glutamate
receptor activation enhances depalmitoylation of PSD-95 (El-
Husseini et al., 2002),while blockadeof synaptic activity enhances
PSD-95 palmitoylation through regulated translocation of the
dendritic palmitoyl acyltransferase (PAT) DHHC2 (Noritake et al.,
2009). Palmitoylation influences synaptic dynamics by augment-
ing clustering of PSD-95 at dendritic spines (Craven et al., 1999).
Palmitoylation of PSD-95 takes place at cysteines 3 and 5
(Topinka and Bredt, 1998). Nitric oxide signals in large part by
S-nitrosylating (hereafter referred to as ‘‘nitrosylating’’) cysteines
in a variety of proteins (Hess et al., 2005). Hess et al. (1993)
showed that NO donors can inhibit the palmitoylation of several
proteins in dorsal root ganglia neurons and suggested that
a NO-mediated posttranslational modification might compete
with palmitoylation. Because of its close physical proximity to
both the NMDA receptor and nNOS, we wondered whether
PSD-95 might be a target for nitrosylation and whether there
might be some interaction between putative nitrosylation and
palmitoylation of PSD-95. In the present study we show that
PSD-95 is physiologically nitrosylated at cysteines 3 and 5 in
a reciprocal relationship with palmitoylation. This process
impacts the physiologic clustering of PSD-95 at synapses.Neuron 71, 131–141, July 14, 2011 ª2011 Elsevier Inc. 131
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Figure 1. PSD-95 Is Nitrosylated on C3
and C5
(A) Nitrosylation of PSD-95 in heterologous cells.
HEK293 cells were transfected with PSD-95-
FLAG, treated with the indicated concentrations of
Cys-NO for 5 min, and analyzed by the biotin
switch.
(B) Basal nitrosylation of endogenous PSD-95 in
mouse brain demonstrated by abolition of the
biotin-switch SNO-PSD-95 signal in nNOS/
brain homogenate when compared to wild-type.
Ascorbate dependence demonstrates specificity
of the signal.
(C) Basal nitrosylation of endogenous PSD-95 and
NR2A in mouse brain demonstrated by abolition of
the biotin-switch SNO-PSD-95 signal in nNOS/
brain homogenate when compared to wild-type.
Both proteins are nitrosylated at comparable
levels.
(D) Nitrosylation of PSD-95-C3 and C5 by physi-
ologically generated NO. HEK-nNOS cells were
transfected with either full-length or truncated
(PSD-95-1-433-FLAG, containing PDZ1-3) PSD-
95 and analyzed by the biotin-switch assay. The
SNO-PSD-95-1-433 signal demonstrates nitrosylation of C3 and C5, as these are the only two cysteines present in the fragment.
(E) Nitrosylation of single cysteine mutants. HEK-nNOS cells transfected with wild-type or the indicated mutants of PSD-95-1-433-FLAG were analyzed by the
biotin switch.
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Nitrosylation of PSD-95RESULTS
PSD-95 Is Physiologically Nitrosylated
at Cysteines 3 and 5
We examined the possibility that PSD-95 can be nitrosylated by
exposing HEK293 cells containing overexpressed PSD-95 to the
NO donor cysteine-NO (Cys-NO) (Figure 1A). The NO donor
elicits nitrosylation of PSD-95, monitored by the biotin-switch
assay, in a concentration-dependent fashion. To determine
whether PSD-95 is physiologically nitrosylated in mammalian
brain, we monitored endogenous PSD-95 in mouse brain from
wild-type and nNOS-deleted animals (Figure 1B). We observe
ascorbate-dependent basal nitrosylation of endogenous
PSD-95 that is abolished in nNOS knockout mice. Levels of
nitrosylated PSD-95 are comparable to those of the NR2A
subunit of the NMDAR (Figure 1C).
PSD-95 is palmitoylated at cysteines 3 and 5 (Topinka and
Bredt, 1998). These occur in the N-terminal 60% of the protein,
which contains the three PDZ domains that are sufficient for
synaptic targeting in the context of endogenous PSD-95 expres-
sion (Craven et al., 1999; Sturgill et al., 2009). While PSD-95
contains six cysteines, only two of these (C3 and C5) occur in
the N-terminal fragment (amino acids 1-433), which we desig-
nate PSD-95-1-433. We observe similar levels of nitrosylation
for full-length PSD-95 and PSD-95-1-433 in HEK-nNOS cells
(Figure 1D). In HEK-nNOS cells nitrosylation of PSD-95-1-433
is abolished with mutation of both C3 and C5 with intermediate
effects in the individual C3 and C5 mutants (Figure 1E).
Palmitoylation of PSD-95 Is Physiologically
Regulated by NO
Because PSD-95 is palmitoylated and nitrosylated at the same
cysteines, we wondered whether the two processes might be132 Neuron 71, 131–141, July 14, 2011 ª2011 Elsevier Inc.mutually competitive. Consistent with this hypothesis, stable
overexpression of nNOS in HEK293 cells substantially dimin-
ishes palmitoylation of full-length PSD-95 as measured by
[3H]palmitate incorporation (Figure 2A). Inhibition of nNOS in
these cells by the nNOS-selective inhibitor N5-(1-imino-3-bu-
tenyl)-L-ornithine (L-VNIO) increases PSD-95 palmitoylation,
while transient expression of nNOS in 293 cells reduces PSD-
95 palmitoylation when measured directly by the acyl biotin
exchange (ABE) procedure (Figures 2B and 2C). This method
is analogous to the biotin-switch method but uses hydroxyl-
amine to reverse palmitoylation (Drisdel et al., 2006).
To confirm that NO is the mediator of these effects, we treated
293 cells with Cys-NO, which markedly reduces [3H]palmitate
incorporation into PSD-95 (Figure 2D). NO donor treatment simi-
larly reduces palmitoylation of PSD-95-1-433. The action of NO
upon PSD-95 palmitoylation is selective. Thus, HRas is physio-
logically palmitoylated and nitrosylated, but the two processes
occur at different sites of the protein (Hancock et al., 1989;
Lander et al., 1996). NO donor treatment fails to alter palmitoyla-
tion of HRas (Figure 2E).
Weexplored the influenceofNOuponpalmitoylationofPSD-95
in mammalian brain. In both cerebellar granule and hippocampal
cultures, palmitoylation, monitored with [3H]palmitate, is virtually
abolished by NO donor treatment (Figures 3A and 3B) concomi-
tant with increases in PSD-95 nitrosylation (Figures 3C and 3D).
We wondered whether endogenous NO regulates palmitoyla-
tion of PSD-95 in the brain. Because nNOS is highly expressed in
granule cells of the cerebellum, we chose to focus on this
system. Utilizing the ABE assay in cerebellar granule cells, we
detect robust palmitoylation of endogenous PSD-95, which is
significantly enhanced by treatment with L-VNIO (Figure 3E).
Thus, endogenous NO physiologically diminishes levels of
PSD-95 palmitoylation.
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Figure 2. Nitric Oxide Inhibits PSD-95 Palmitoylation in Heterologous Cells
(A) nNOS expression correlates with decreased palmitoylation of PSD-95. HEK293 or HEK-nNOS cells were transfected with PSD-95-FLAG and metabolically
labeled with [3H]palmitate. Shown are immunoprecipitation (IP) and detection of incorporated [3H] into PSD-95-FLAG (top panel). Input and expression were
confirmed by western blot (WB, bottom panel). Shown are a representative result (top) and quantification (bottom). Palmitoylated PSD-95 was measured by
scanning densitometry, normalized to input, and expressed as a percentage of the untreated sample. Data are means ± SEM (n = 3). *p < 0.02 by Student’s t test
relative to untreated 293 cells.
(B) Pharmacologic nNOS inhibition in HEK-nNOS cells increases PSD-95 palmitoylation. HEK-nNOS cells transiently transfected with PSD-95-FLAGwere treated
with 20 mM L-VNIO overnight and PSD-95 palmitoylation was measured by the ABE assay.
(C) nNOS expression correlates with decreased palmitoylation of PSD-95. HEK293 cells were cotransfected with PSD-95-FLAG and either nNOS or empty vector
control. PSD-95 palmitoylation was measured by the ABE assay.
(D) Concentration-dependent inhibition of palmitoylation of PSD-95 by Cys-NO. HEK293 cells expressing PSD-95-FLAG were metabolically labeled with
[3H]palmitate followed by FLAG IP, Coomassie (CBB) stain, and fluorography of the same gel.
(E) Specificity of NO-mediated inhibition of palmitoylation. HEK293 cells were cotransfected with PSD-95-1-433-FLAG andmEGFP-HRas and analyzed as in (D).
Shown are a representative result (top) and quantification (bottom), analyzed as in (A). Data are means ± SEM (n = 3). *p < 0.05.
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Nitrosylation of PSD-95Blocking synaptic activity with tetrodotoxin (TTX) increases
palmitoylation of several proteins including PSD-95 (Hayashi
et al., 2009; Noritake et al., 2009). Nitrosylation of PSD-95 is
decreased and palmitoylation increased in neurons treated
with TTX (Figures 3F and 3G).
NMDAR-mediated neurotransmission is known to stimulate
NO formation (Bredt and Snyder, 1989). We conducted experi-
ments to assess its impact on palmitoylation. NMDA treatment
of granule cells reduces palmitoylation of PSD-95 by 70%
(Figure 2H). This action reflects NMDA augmentation of NO
formation, as it is largely reversed by treatment with L-VNIO.
Moreover, we observe reciprocal changes in PSD-95 nitrosyla-
tion, suggesting that nitrosylation is responsible for the effects
of NMDA-mediated NO formation (Figure 3I). To further explore
the importance of endogenous NO in regulating PSD-95 palmi-
toylation, we made use of nNOS-deleted mice (Figure 3J). We
confirm the marked reduction of PSD-95 palmitoylation in
response to NMDA treatment. Levels of PSD-95 palmitoylation
are significantly augmented in nNOS-deleted granule cells bothin the absence and presence of NMDA treatment (Figure 3J).
NMDA does elicit some decrease in PSD-95 palmitoylation in
nNOS knockout mice, which may reflect the retention of alterna-
tively spliced, catalytically active nNOS (Eliasson et al., 1997) or
compensatory mechanisms involving eNOS or iNOS (Huang
and Fishman, 1996). Thus, diverse experimental approaches
establish that in mammalian brain, endogenous NO under basal
conditions and in response to NMDAR-mediated neurotransmis-
sion regulates the palmitoylation of PSD-95.
Synaptic Clustering of PSD-95 Is Inhibited by NMDA
Transmission in a NO-Dependent Fashion
One of the principal roles of PSD-95 palmitoylation is to regulate
synaptic clustering of the protein. Thus, synaptic clustering of
PSD-95 is abolished with C3 and C5 mutation, which prevents
palmitoylation (Craven et al., 1999). Moreover, inhibition of pal-
mitoylation with 2-bromopalmitate (2-BP) reduces PSD-95
synaptic clusters (El-Husseini et al., 2002). Bredt, Nicoll, and
Fukata established that glutamate neurotransmission, actingNeuron 71, 131–141, July 14, 2011 ª2011 Elsevier Inc. 133
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Figure 3. Nitric Oxide Inhibits Endogenous PSD-95 in Neurons
(A and B) Cys-NO inhibits palmitoylation of endogenous PSD-95. Cerebellar granule (A) or hippocampal (B) neurons weremetabolically labeled in the presence or
absence of 250 mM Cys-NO and analyzed as in Figure 2A.
(C and D) Cys-NO elicits nitrosylation of endogenous PSD-95. Cerebellar granule (C) or hippocampal (D) neuronal cultures were subjected to the biotin-switch
assay after treatment with Cys-NO as in (A) and (B).
(E) L-VNIO treatment increases basal PSD-95 palmitoylation. Cerebellar granule cells were treatedwith 75 mML-VNIO for 8 hr to inhibit nNOS and subjected to the
ABE assay. Hydroxylamine (NH2OH) dependence indicates specificity of the signal. Shown are a representative result (left) and quantification (right), analyzed as
in Figure 2A. Data are means ± SEM (n = 4). *p < 0.04.
(F) TTX increases PSD-95 palmitoylation. Cerebellar granule cells were treated with 2 mM TTX for 4 hr in conditioned media and analyzed by the ABE assay.
(G) TTX decreases PSD-95 nitrosylation. Cerebellar granule cells were treated as in (F) and analyzed by the biotin-switch assay.
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Nitrosylation of PSD-95via ionotropic receptors, diminishes PSD-95 clustering both by
inhibiting palmitoylation (Noritake et al., 2009) and by stimulating
depalmitoylation (el-Husseini and Bredt, 2002). We wondered
whether this process might involve influences of NO acting by
displacing palmitate from PSD-95. Accordingly, we examined
the effect of NMDA treatment upon PSD-95 clustering in cere-
bellar granule neurons and evaluated the influence of the
nNOS inhibitor VNIO (Figure 4). PSD-95 is synaptic in localization
as it is closely apposed to clusters of synapsin, a presynaptic
marker, with statistically significant colocalization (Pearson
correlation coefficient, 0.45) (Figure 4A). NMDA treatment
reduces PSD-95 synaptic clusters by 40%, while VNIO signif-
icantly reverses this action. In contrast, synapsin clusters are
unchanged. The partial reversal by VNIO may indicate that the
NMDA effects involve other signaling systems in addition to
NO, possibly associated with calcium entering cells through
NMDA channels. Double labeling is specific, as demonstrated
by omission of primary antibodies (Figure 5C). As previously re-
ported, 2-BP reduces PSD-95 clustering (Figures 5A and 5B).
Palmitoylation of PSD-95 regulates basal AMPA receptor clus-
tering (El-Husseini et al., 2002). Addition of NMDA to cultured
neurons triggers AMPA receptor endocytosis (Beattie et al.,
2000). Treatment with 2-BP does not further decrease GluR2
surface clusters in neurons exposed to NMDA (Figures 4C and
4D), suggesting that palmitoylated targets including PSD-95
play a role in both basal and NMDA-dependent AMPA receptor
surface clustering.
These experiments establish that NMDAR-mediated neuro-
transmission regulates PSD-95 clustering. The reduction of
PSD-95 clustering in response to glutamatergic transmission
involves NO. The regulation of PSD-95 clustering by NO reflects
its influence upon palmitoylation of PSD-95.
Palmitoylation Physiologically Regulates Nitrosylation
of PSD-95
Nitrosylation is increasingly appreciated as a major posttransla-
tional modification of proteins (Cho et al., 2009; Hess et al., 2005;
Whalen et al., 2007). Besides nitrosylation and palmitoylation,
cysteines of proteins are physiologically modified by oxidative
mechanisms involving hydrogen peroxide and other agents, as
well as by glutathionylation, sulfhydration, and the formation of
disulfide bonds. With the exception of disulfides (Takahashi
et al., 2007), thus far there has been no evidence for physiologic
regulation of nitrosylation by these other posttranslational modi-
fications of cysteines. We asked whether palmitoylation might
normally modulate levels of nitrosylated PSD-95. In HEK-nNOS
cells nitrosylation of PSD-95-1-433 is demonstrable and is lost
with mutation of C3 and C5 (Figure 6A). Nitrosylation of PSD-
95-1-433 is substantially augmented by treatment with 2-BP,(H) NMDAdecreases PSD-95 palmitoylation in anNO-dependent manner. Cerebe
10 min with or without 1 hr of 75 mM VNIO pretreatment, returned to normal med
quantification (right), analyzed as in (E). Data are means ± SEM (n = 3). *p < 0.02
(I) NMDA elicits PSD-95 nitrosylation in an NO-dependent manner. Nitrosylation o
after treatment with NMDA and/or VNIO as in (H).
(J) Increased PSD-95 palmitoylation in nNOS/ cultures. Cerebellar granule cell
(H) and analyzed by ABE. Shown are a representative result (top) and quantificatio
untreated wild-type mice; #p < 0.02 relative to wild-type mice + NMDA.indicating that endogenous palmitoylation reduces levels of
PSD-95 nitrosylation. This reciprocity of nitrosylation and palmi-
toylation is selective. Thus, b-tubulin is known to be nitrosylated
(Jaffrey et al., 2001) but has not been conclusively shown to be
palmitoylated in vivo. Nitrosylation of tubulin is unaffected by
2-BP.
To assess whether endogenous palmitoylation of PSD-95
physiologically regulates its nitrosylation in intact animals, we
examined brains of mice with targeted deletion of the palmitoyl
acyltransferase enzymeZDHHC8,which has beendemonstrated
tobeaphysiologicPAT forPSD-95 (Mukaietal., 2008) (Figure6B).
Levels of nitrosylation of PSD-95 are increased 3-fold in the
ZDHHC8 knockout brains. By contrast, nitrosylation of GAPDH,
which is not physiologically palmitoylated, is unaltered in the
mutant mice. The proportionally larger increase in nitrosylation
of PSD-95 compared to palmitoylation may be due to higher
levels of palmitoylated PSD-95 in unstimulated brains with low
basal levels ofNO.Asmall change inpalmitoylationmay therefore
result in a larger percentage change in nitrosylation of PSD-95.
Neither palmitoylation (Hayashi et al., 2009) nor nitrosylation
(Choi et al., 2000) of NR2A, which occurs on distinct cysteines,
is affected in the mutant mice (Figure 6C). Thus, nitrosylation of
PSD-95 is physiologically modulated by palmitoylation.
NO is known to regulate NMDA receptors in a feedback
fashion, inhibiting their function by nitrosylating them (Choi
et al., 2000). PSD-95 serves as a conduit for NMDA receptors
to activate nNOS, generating NO (Christopherson et al., 1999).
We wondered whether the generated NO might feed back to
regulate palmitoylation of PSD-95 through nitrosylation. Accord-
ingly, we examined the binding of NR2B to PSD-95 in mice with
ZDHHC8 deletion to determine whether higher levels of nitrosy-
lated PSD-95 present in these mutant mice are associated with
decreased NR2B-PSD-95 binding (Figure 6D). This binding is
substantially reduced in the mutant mice. While deficient palmi-
toylation and mislocalization of PSD-95 may be involved in the
decreased binding (Li et al., 2003), our results are consistent
with the hypothesized feedback model.
DISCUSSION
NO is well established as a modulator of synaptic transmission
throughout the brain (Bredt, 1999). PSD-95, the principal
component of postsynaptic densities, is a scaffolding protein
that influences synaptic transmission. PSD-95 binds nNOS,
facilitating the linkage of NMDAR-mediated neurotransmission
to activation of nNOS by calcium that passes through NMDA
ion channels (Christopherson et al., 1999; Sattler et al., 1999).
Heretofore, there has been no evidence for any reciprocal influ-
ence of NO upon PSD-95. Our study provides compellingllar granule cells were treatedwith 300 mMNMDAand 10 mMglycine in ACSF for
ia for 8 hr, and analyzed by ABE. Shown are a representative result (left) and
relative to NMDA treated.
f PSD-95 in cerebellar granule cells was measured by the biotin-switch assay
s derived from either wild-type or nNOS/mice were treated with NMDA as in
n (bottom), analyzed as in (E). Data are means ± SEM (n = 4). *p < 0.05 relative to
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Figure 4. NO Inhibits PSD-95 Clustering
(A) Representative images of PSD-95 clusters (green) and their localization in synapsin (red)-labeled cerebellar granule neurons at DIV 12. Cells were treated with
100 mM NMDA in ACSF with or without 1 hr of 100 mM L-VNIO pretreatment. Scale bar = 10 mm.
(B) Reduction in the number of PSD-95 clusters with NMDA partially reversed by L-VNIO. Quantified data were generated as described in Experimental
Procedures. Data are expressed as means ± SEM. *p < 0.02 relative to NMDA treated by Student’s t test.
(C) Representative images of the dendritic expression of live-stained surface GluR2 by using an N-terminal antibody (green) and VGLUT1 (red) in MAP2 (blue)-
labeled hippocampal neurons at DIV 15. Neurons were treated with or without 20 mM 2-BP for 8 hr and then treated with or without 100 mM NMDA for 10 min.
Scale bar = 2 mm.
(D) Reduction in the number of surface GluR2 clusters with 2-BP treatment is not further increased by NMDA treatment. Quantified data were generated as
described in Experimental Procedures. *p = 0.002, **p = 0.0005, ***p = 0.00001.
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Nitrosylation of PSD-95evidence that NO physiologically nitrosylates PSD-95. Synaptic
clustering of PSD-95, a process that determines its influence
upon synaptic transmission, is critically dependent upon its pal-
mitoylation (Craven et al., 1999). Our observation that nitrosyla-
tion and palmitoylation of PSD-95 are reciprocal events indicates
that NO normally impacts major functions of PSD-95. We also
observed that palmitoylation physiologically regulates nitrosyla-
tion of PSD-95.136 Neuron 71, 131–141, July 14, 2011 ª2011 Elsevier Inc.El-Husseini et al. (2002) have established that glutamatergic
transmission leads to the depalmitoylation of PSD-95 with
attendant influences upon synaptic events. Their studies did
not indicate a specific molecular mechanismwhereby glutamate
transmission enhances depalmitoylation. Noritake et al. (2009)
presented evidence for inhibition of palmitoylation by transloca-
tion of the DHHC2 PAT out of the PSD. Our study provides
a well-defined mechanism linking glutamatergic transmission
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Figure 5. Effects of 2-Bromopalmitate on PSD-95 and Specificity of Double Immunostaining
(A) Representative images of PSD-95 clusters (green) and their localization in synapsin (red)-labeled cerebellar granule neurons at DIV 12. Cells were treated with
10 mM 2-BP in conditioned media for 8 hr. Scale bar = 10 mm.
(B) Reduction in the number of PSD-95 clusters with 2-BP treatment. Quantified data were generated as in Figure 4. Data are means ± SEM. *p < 0.001 relative to
untreated neurons by Student’s t test.
(C) Verification of double immunolabeling specificity. Cells were stained as in Figure 4 with omission of either PSD-95 or synapsin primary antibody.
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Nitrosylation of PSD-95and palmitoylation (Figure 7). Glutamate-NMDA neurotransmis-
sion leads to depalmitoylation of PSD-95 as reported by El-Hus-
seini et al. (2002). Calcium entering cells via the NMDA ion
channel binds to calmodulin associated with nNOS, causing
NO formation. Generated NO nitrosylates PSD-95 in a process
competitive with palmitoylation, blocking free cysteines and
maintaining PSD-95 in the depalmitoylated state. Augmented
NMDA transmission and associated NO formation thereby lead
to decreased palmitoylation of PSD-95.
We have also shown that this regulation is reciprocal. While
NO inhibits palmitoylation, endogenous palmitoylation also
regulates nitrosylation of PSD-95. We demonstrate that deletion
of a PSD-95 PAT, ZDHHC8, results in increased nitrosylation of
PSD-95 concomitant with a decrease in binding of PSD-95 and
NR2B. It is unknown whether or not ZDHHC8 has activity toward
NR2B. Thus the potential contribution of altered NR2B palmitoy-
lation in the ZDHHC8/ mouse to decreased binding with
PSD-95 remains to be clarified. ZDHHC8 is primarily localized
in a perinuclear domain and in dendritic shafts of mature neurons
with partial colocalization with PSD-95 at these sites (Mukai
et al., 2004, 2008).
Several depalmitoylating enzymes have been described,
including APT1 and PPT1 (Fukata and Fukata, 2010). None ofthem has been shown to act upon PSD-95 directly. Thus, their
role in regulating PSD-95 palmitoylation is unclear. Conceivably
such depalmitoylating enzymes might act in conjunction with
NO to influence the state of palmitoylation of PSD-95.
The modulation of PSD-95 palmitoylation by glutamatergic
transmission is reversed by CNQX, a drug that blocks AMPA
receptors, and by AP5, an inhibitor of NMDA receptors, as well
as by kynurenic acid, which blocks both ionotropic glutamate
receptors (El-Husseini et al., 2002). From these limited experi-
ments one cannot assess the relative contribution of various
subtypes of ionotropic glutamate receptors to the palmitoylation
process. Moreover, there are no data available regarding the
impact of metabotropic glutamate transmission upon PSD-95
palmitoylation. Our experiments emphasize the role of NMDA
transmission in PSD-95 palmitoylation. Clarification of the
detailed interaction of various types of glutamate transmission
in influencing the counterbalance of NO and palmitoylation for
regulation of PSD-95 awaits further investigation.
There is precedent for competing posttranslational modi-
fications influencing protein function, most notably with acety-
lation and ubiquitination (Ge et al., 2009; Giandomenico et al.,
2003; Gro¨nroos et al., 2002). Thus, the dynamic reciprocity
between palmitoylation and nitrosylation of PSD-95 may reflectNeuron 71, 131–141, July 14, 2011 ª2011 Elsevier Inc. 137
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Figure 6. Palmitoylation Regulates PSD-95 Nitrosylation
(A) 2-BP treatment of HEK-nNOS cells increases nitrosylation. HEK-nNOS cells expressing PSD-95-1-433-FLAG or the corresponding C3 , C5S mutant were
treated with 100 mM 2-BP for 4 hr and analyzed by biotin switch. b-tubulin is a control nitrosylated protein unaffected by 2BP treatment. Shown are a repre-
sentative result (left) and quantification of nitrosylated PSD-95-1-433-FLAG (right), analyzed as in Figure 2. Data are means ± SEM (n = 3). *p < 0.02 relative to
untreated HEK-nNOS cells.
(B) ZDHHC8/mice have increased endogenous SNO-PSD-95. Brain homogenates from age-matchedwild-type or ZDHHC8/micewere analyzed by biotin
switch and ABE. Shown are a representative result (left) and quantification for the biotin switch (middle), analyzed as in (A). Data aremeans ± SEM (n = 3). *p < 0.04
relative to wild-type. Shown is quantification for ABE. Data are means ± SEM (n = 3). *p < 0.05 relative to wild-type. GAPDH nitrosylation is also demonstrated but
does not increase in the ZDHHC8/ mouse.
(C) Basal nitrosylation of NR2A was demonstrated in wild-type and ZDHHC8/ mouse brain by the biotin-switch assay. Palmitoylation was measured by the
ABE assay.
(D) Decreased binding of NR2B to PSD-95 in ZDDHC8/mice. NR2B was immunoprecipitated from ZDHHC8/ or wild-type brain homogenate and blotted
for PSD-95.
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Nitrosylation of PSD-95a process that occurs with other proteins that are nitrosylated
and palmitoylated at the same sites. Nitrosylation is a very
common posttranslational modification affecting more than
100 proteins (Hess et al., 2005). Palmitoylation is similarly prev-
alent with at least 68 proteins in mammalian brain known to be
palmitoylated plus an additional 200 candidates recently found
in a proteomic screen (Kang et al., 2008). We are not aware of
other studies in which reciprocal nitrosylation and palmitoyla-
tion have been characterized for individual proteins at the
same sites. Because of the large numbers of proteins that are
nitrosylated and/or palmitoylated, we suspect that interactions
between these two processes are frequent and that they
mediate numerous physiologic processes both in the brain
and periphery.138 Neuron 71, 131–141, July 14, 2011 ª2011 Elsevier Inc.Sulfhydration, a posttranslational modification elicited by the
gasotransmitter actions of H2S (Mustafa et al., 2009) also might
influence PSD-95. H2S signaling via sulfhydration differs in some
respects from nitrosylation. A more stable modification, sulfhy-
dration often activates proteins, because the SH becomes an
even more reactive SSH, while nitrosylation often inactivates
a reactive cysteine by converting the reactive SH to SNO.
Whether putative sulfhydration of PSD-95 would functionally
alter the protein differently from nitrosylation is unclear.
PSD-95 exerts its physiologic effects by binding to a variety of
protein partners. Conceivably, nitrosylation of PSD-95 affects
such binding. For instance, AKAP links PSD-95 to AMPA
receptor endocytosis (Bhattacharyya et al., 2009). NMDA neuro-
transmission, via nitrosylation of PSD-95, might impact
Figure 7. Model for NO-Mediated Regula-
tion of PSD-95 Synaptic Targeting
While palmitoylated (red wavy lines), PSD-95 is
stably associated with the PSD (orange region).
NMDA stimulation promotes depalmitoylation
through a putative palmitoyl protein thioesterase
(PPT) (El-Husseini et al., 2002). Simultaneously,
calcium entering cells through the NMDA ion
channel activates nNOS by binding to calmodulin,
causing NO formation. NO generated in close
proximity to PSD-95 nitrosylates PSD-95,
blocking free cysteines and preventing re-
palmitoylation by PSD-95 PATs and subsequent
association with the PSD.
Neuron
Nitrosylation of PSD-95interactions with AKAP and provide another means of linking
NMDA and AMPA receptors. Similarly, stargazin, which is phys-
iologically nitrosylated (Selvakumar et al., 2009), binds to PSD-
95 as well as AMPA receptors. Nitrosylation of PSD-95 might
influence its binding to stargazin and thereby to AMPA receptors.
Nitrosylation of stargazin facilitates its augmentation of the
surface expression of AMPA receptors (Selvakumar et al.,
2009). One might speculate that NMDA transmission would
enhance nitrosylation of both PSD-95 and stargazin with
complex influences upon AMPA receptor disposition.
EXPERIMENTAL PROCEDURES
Cell Culture
HEK293 andHEK-nNOScells were cultured in DMEMwith 10%FBS, 2%peni-
cillin-streptomycin, 2 mM L-glutamine, and 8 g/ml tylosin (Sigma-Aldrich).
Dissociated granule cells were prepared frommouse cerebellum as described
(Kato et al., 2007) and plated at a density of 53 106 cells/6 cmdish.Dissociated
hippocampal neurons were prepared from E18 mice as described (Kang et al.,
2010). For NMDA treatments prior to ABE analysis, cells with or without 1 hr of
L-VNIOpretreatmentwere stimulatedwith 300mMNMDAand10mMglycine for
10min in ACSF (10mMHEPES, 10mMD-glucose, 2mMCaCl2, 3mMKCl, and
124mMNaCl, pH 7.4) and returned to growthmedia for 8 hr. For basal L-VNIO
treatments, 75 mM L-VNIO was added to growth media for 8 hr.
Antibodies and Reagents
Antibodies were purchased from the following companies: PSD-95 (7E3-1B8)
was from Millipore for biochemistry, with the exception of Figure 3G, where
PSD-95 (6G6 1C9, Millipore) was used. PSD-95 (MA1-046) was from Affinity
Bioreagents for immunostaining; GADPH was from Santa Cruz (rabbit);
NR2B (ZK11) was from Invitrogen for immunoprecipitation; and synapsin (H-
170) was from Santa Cruz. FLAG M2 and conjugated beads were from Sigma
and anti-GFP agarose was fromMBL. NR2B and NR2A antibodies for western
blotting (C-terminal) were generous gifts from Richard Huganir. L-VNIO was
from Alexis and NMDA and 2-bromopalmitate were from Sigma.
Plasmids and Transfections
pgW.1-PSD-95-FLAGwas a generous gift fromDavid Bredt. Cysteine mutants
and pgW.1-PSD-95-1-433-FLAGwere generated by using standard protocols
for Phusion DNA polymerase (Finnzymes, Thermo Fisher Scientific). mEGFP-
HRAS (Addgene plasmid 18662) was purchased from Addgene (Yasuda
et al., 2006). Plasmids were transfected by using polyfect (QIAGEN) following
the manufacturer’s instructions. For all experiments, cells were lysed 24 hr
after transfection.Biotin-Switch Assay
Cell extracts or homogenates from age-matched mouse brain samples were
analyzed by the biotin-switch assay as described with minor modifications
(Jaffrey and Snyder, 2001). Briefly, 293 cells at 95% confluency or cerebellar
granule cells seeded at 1 3 107 cells per dish were extracted in HEN buffer
(250 mM HEPES, 1 mM EDTA, and 0.1 mM neocuproine, pH 7.7) containing
1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, and 200 mM desfer-
oxamine, with protease and phosphatase inhibitors (Sigma). Extracts were
treated with methylmethanethiosulfonate (Sigma) in 2.5% SDS at 50C for
20 min. Proteins were precipitated with acetone and labeled with biotin-
HPDP (0.8 mM) (Pierce) with or without 50 mM ascorbate for 90 min at room
temperature. Proteins were precipitated twice with acetone and biotinylated
proteins were purified by using neutravidin beads (Pierce), separated by
SDS-PAGE, and analyzed by western blotting.
Metabolic Labeling with [3H]Palmitate
[3H]palmitate was purchased from NEN and concentrated by using a Speed-
vac. Cells were labeled in PBS with 0.1 mCi/ml palmitate (293 cells) or
0.5 mCi/ml palmitate in ACSF (neurons). Lysis was performed in modified
RIPA buffer (50 mM Tris, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1%
sodium deoxycholate, and 0.1% SDS) and proteins of interest were immuno-
precipitated with the appropriate antibody overnight followed by a 2 hr incuba-
tion with protein A/G-conjugated agarose (Calbiochem). Proteins were eluted
at 70C in NuPage sample buffer (2 3) (Invitrogen) containing 1 mM DTT and
separated on SDS-PAGE. For experiments with 293 cells, gels were stained
with SimplyBlue (Invitrogen); for neuronal experiments, 10% of each eluate
was western blotted for input controls. Gels for fluorography were soaked in
Amplify (Amersham) for 30 min, dried under vacuum at 70C, and exposed
for 3–4 days (overexpressed protein) or 3–4 weeks (endogenous protein).
ABE Assay
Cell extracts or homogenates from age-matched brain samples were analyzed
by the acyl-biotin exchange assay as described withminor modifications (Wan
et al., 2007). Briefly, cells were lysed in buffer containing 50 mM Tris, 50 mM
NaCl, 1 mM EDTA, and 2% SDS, supplemented with protease inhibitors.
Extracts were sonicated briefly and treated with 10 mM NEM for 20 min at
37C. Proteins were precipitated with acetone and labeled with biotin-HPDP
(0.8 mM) in buffer containing either 0.56 M hydroxylamine, pH 7.4, or 0.56 M
Tris, pH 7.4, for 1 hr at room temperature. Proteins were run through a Zeba
desalting column (Pierce) followed by acetone precipitation. Biotinylated
proteins were purified with neutravidin beads (Pierce), separated by SDS-
PAGE, and analyzed by western blotting.
Immunostaining and Image Analysis
Neurons were seeded at a density of 13 106 cells/well onto polylysine coated
Lab-Tek two-well chamber slides. At DIV 12, samples were treated withNeuron 71, 131–141, July 14, 2011 ª2011 Elsevier Inc. 139
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Nitrosylation of PSD-95100 mM NMDA in ACSF for 10 min with or without 100 mM VNIO pretreatment
for 1 hr andwere returned to normal media for 8 hr. Cells were fixed in 4%para-
formaldehyde for 20 min, blocked in 5% goat serum with 0.1% Triton X-100 in
PBS for 1 hr, and stained overnight at 4C for PSD-95 (1:200) or synapsin
(1:100) in blocking solution. Appropriate secondary antibodies conjugated to
AlexaFluor 488 and 567 (Molecular Probes) were incubated with samples for
1 hr at room temperature after three washes with TBST. Slides were prepared
by using Fluormount G (Southern Biotech) and images were taken with a Zeiss
510 Meta confocal microscope at 633. Analysis of PSD-95 clusters was per-
formed as described (Mukai et al., 2008). Briefly, the particle measurement
function of ImageJwas used to count discrete fluorescent puncta in a proximal
20 mM section of the largest one or two dendrites per neuron. Settings of
minimal punctum size and threshold were maintained constant across all
treatment conditions. Pearson’s coefficients were calculated by using the
colocalization threshold plugin for ImageJ.
Analysis of GluR2 Surface Clustering
Hippocampal neurons were treated with and without 20 mM2-bromopalmitate
for 8 hr. For live staining, neurons (DIV 15) were incubated with 50 mg/ml anti-
GluR2 N-terminal antibody (Millipore) in conditioned medium for 15 min at
37C. Neurons were fixed with 4% PFA for 10 min on ice, blocked in 5 mg/ml
bovine serum albumin in PBS for 10 min, and stained with secondary antibody
under unpermeabilized conditions. Neuronswere then permeabilized to detect
the antigen. Images were taken with a confocal laser microscopy system (Carl
Zeiss LSM510;Carl Zeiss). The number ofGluR2fluorescent puncta, which are
merged with VGLUT1, was calculated as surface GluR2 by using ImageJ. To
quantitate changes in clustering, we chose twelve fields from two independent
neuronal cultures and analyzed the largest proximal dendrite (30 mm long).
Coimmunoprecipitation
Proteins from brain homogenate were extracted withmodified RIPA buffer and
incubated with anti-NR2B antibody (Invitrogen) overnight followed by a 2 hr
incubation with protein A/G agarose-conjugated beads (Calbiochem). Beads
were washed three times inmodified RIPA, aspirated to dryness with a syringe,
eluted with 2 3 LDS, and analyzed by SDS-PAGE.
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